We are closed on November 23rd and November 24th in observance of Thanksgiving. View More Important Notifications x
texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials
print
Texas Oncology-Austin Central
6204 Balcones Drive, Austin, TX 78731
T: 512-427-9400
After HoursT: 512-427-9400
Hours of Operation:




Pharmacy Hours of Operation:




New Patient Forms

Texas Oncology-Austin Central Research and Clinical Trials

We participate in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials. Learn more and see a list of current trials.

Breast Cancer

Phase:

Title: MRI evaluation of breast tumor growth and treatment response View

Lung Cancer

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Phase: III/IV

Title: CA209-817: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer View

Phase: III

Title: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) View

Phase: III

Title: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (Keynote-604) View

Lymphomas

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Phase: I/II

Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101 View

Melanoma

Phase:

Title: A US Multi-Site Observational Study in Patients with Unresectable and Metastatic Melanoma: the Optimize Study View

Mesothelioma

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Myelomas

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Phase: II

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Neuroendocrine Tumors

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Ovarian Cancer

Phase: III

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Phase: II

Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens - Tesaro PR-30-5020-C - QUADRA View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer View

Phase: III

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Phase: III

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Phase: II

Title: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105) View

Pancreatic Cancer

Phase: III

Title: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Penile Cancer

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Prostate Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385 View

Rectal Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) View

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Renal Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Phase: III

Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER) View

Solid Tumors

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Testicular Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thymomas

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thyroid Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Urothelial Cancer

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Uterine Cancer

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Vaginal Cancer

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

No Phase

Indication: Melanoma

Title: A US Multi-Site Observational Study in Patients with Unresectable and Metastatic Melanoma: the Optimize Study View

Indication: Breast Cancer

Title: MRI evaluation of breast tumor growth and treatment response View

Phase I

Indication: Lymphomas

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Phase I/II

Indication: Lymphomas

Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101 View

Phase II

Indication: Lung Cancer

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lymphomas

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Mesothelioma

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Myelomas

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Indication: Neuroendocrine Tumors

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Ovarian Cancer

Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens - Tesaro PR-30-5020-C - QUADRA View

Indication: Ovarian Cancer

Title: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105) View

Indication: Penile Cancer

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Uterine Cancer

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Phase II/III

Indication: Mesothelioma

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Phase III

Indication: Lung Cancer

Title: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) View

Indication: Lung Cancer

Title: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (Keynote-604) View

Indication: Lymphomas

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Neuroendocrine Tumors

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Ovarian Cancer

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Indication: Ovarian Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Ovarian Cancer

Title: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer View

Indication: Ovarian Cancer

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Indication: Ovarian Cancer

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Indication: Pancreatic Cancer

Title: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) View

Indication: Pancreatic Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Prostate Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Prostate Cancer

Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385 View

Indication: Rectal Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) View

Indication: Rectal Cancer

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Renal Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER) View

Indication: Solid Tumors

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase III/IV

Indication: Lung Cancer

Title: CA209-817: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer View

Indication: Renal Cancer

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Phase IV

Indication: Myelomas

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View